Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: Results of 48-month study

Clinical Research in Cardiology

Volumn 101, Issue 8, 2012, Pages 631-636

  Zhang, Ruoyu ^a   Bobylev, Dmitry ^a   Stiefel, Penelope ^a   Haverich, Axel ^a   Bara, Christoph ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Corrected QT interval; Drugs; Follow up studies; Heart transplantation; Ivabradine

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; EVEROLIMUS; IVABRADINE; METOPROLOL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ARTICLE; BLOOD PRESSURE; BRADYCARDIA; CARDIAC GRAFT REJECTION; CLINICAL ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART CONDUCTION; HEART GRAFT; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART RATE; HUMAN; MALE; QT INTERVAL; TACHYCARDIA; VERTIGO;

ADMINISTRATION, ORAL; ANTI-ARRHYTHMIA AGENTS; BENZAZEPINES; ELECTROCARDIOGRAPHY; FEMALE; HEART TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TACHYCARDIA, SINUS; TREATMENT OUTCOME;

EID: 84865782156     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-012-0436-2     Document Type: Article

References (29)

1. Borer JS, Fox K, Jaillon P, Lerebours G, Ivabradine Investigators Group (2003) Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: A randomized, double-blinded, multicentered, placebo-controlled trial. Circulation 107:817-823
2. Lopez-Bescos L, Filipova S, Martos R (2007) Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology 108:387-396
3. Ruzyllo W, Tendera M, Ford I, Fox KM (2007) Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: A 3-month randomised, double-blind, multicentre, noninferiority trial. Drugs 67:393-405
4. Tardif JC, Ford I, Tendera M et al (2005) Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 26:2529-2536
5. Nuding S, Ebelt H, Hoke RS, Krummenerl A, Wienke A, Müller-Werdan U, Werdan K (2011) Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine: MODI (f)Y trial. Clin Res Cardiol 100:915-923
6. Vitale D, De Santis V, Guarracino F, Fontana A, Pellegrini F, Tritapepe L (2010) Use of ivabradine in catecholamine-induced tachycardia after high-risk cardiac surgery. Clin Res Cardiol 99:853-855
7. Koester R, Kaehler J, Meinertz T (2011) Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol 100:121-128
8. Koester R, Kaehler J, Ebelt H, Soeffker G, Werdan K, Meinertz T (2010) Ivabradine in combination with beta-blocker therapy for the treatment of stable angina pectoris in every day clinical practice. Clin Res Cardiol 99:665-672
9. Wenzel P, Abegunewardene N, Münzel T (2009) Effects of selective I f-channel inhibition with ivabradine on hemodynamics in a patient with restrictive cardiomyopathy. Clin Res Cardiol 98:681-684
10. Link A, Reil JC, Selejan S, Böhm M (2009) Effect of ivabradine in dobutamine induced sinus tachycardia in a case of acute heart failure. Clin Res Cardiol 98:513-515
11. Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, SHIFT Investigators (2010) Heart rate as a risk factor in chronic heart failure (SHIFT): The association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 376:886-894
12. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, BEAUTIFUL Investigators (2008) Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial. Lancet 372:807-816
13. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, BEAUTIFUL Investigators (2008) Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial. Lancet 372:817-821
14. Kushwaha SS, Banner NR, Patel N, Cox A, Patton H, Yacoub MH (1994) Effect of beta blockade on the neurohumoral and cardiopulmonary response to dynamic exercise in cardiac transplant recipients. Br Heart J 71:431-436
15. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A (1995) Coronary and hemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 275:659-666
16. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP (1994) Electrophysiological effects of S 16257, a novel sinoatrial node Pharmacol modulator, on rabbit and guinea-pig cardiac preparations: Comparison with UL-FS 49. Br J Pharmacol 112:37-42
17. Zhang R, Haverich A, Strüber M, Simon A, Pichlmaier M, Bara C (2008) Effects of ivabradine on allograft function and exercise performance in heart transplant recipients with permanent sinus tachycardia. Clin Res Cardiol 97:811-819
18. Doesch AO, Celik S, Ehlermann P, Frankenstein L, Zehelein J, Koch A, Katus HA, Dengler TJ (2007) Heart rate reduction after heart transplantation with beta-blocker versus the selective If channel antagonist ivabradine. Transplantation 84:988-996
19. Toivonen L (2002) More light on QT interval measurement. Heart 87:193-194
20. Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, Morehead A, Kitzman D, Oh J, Quinones M, Schiller NB, Stein JH, American Society of Echocardiography (2004) American Society of Echocardiography recommendations for use of echocardiography in clinical trials. J Am Soc Echocardiogr 17:1086-1119
21. Doesch AO, Ammon K, Konstandin M, Celik S, Kristen A, Frankenstein L, Buss S, Hardt S, Sack FU, Katus HA, Dengler TJ (2009) Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients. Transplantation 88:835-841
22. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, SHIFT Investigators (2010) Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study. Lancet 376:875-885
23. Taylor DO, Stehlik J, Edwards LB, Aurora P, Christie JD, Dobbels F, Kirk R, Kucheryavaya AY, Rahmel AO, Hertz MI (2009) Registry of the International Society for heart and lung transplantation: Twenty-sixth official adult heart transplant report -2009. J Heart Lung Transplant 28:1007-1022
24. Savelieva I, Camm AJ (2005) Comparison of the effects of a selective If current inhibitor ivabradine and atenolol on the QT interval in patients with coronary artery disease. Heart Rhythm 2:145-146 (abstract)
25. Ward DE (1988) Prolongation of the QT interval as an indicator of risk of a cardiac event. Eur Heart J 9:139-144
26. Darbar D, Fromm MF, Dellorto S, Roden DM (2001) Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol 12:9-14
27. Zhou S, Cao JM, Tebb ZD, Ohara T, Huang HL, Omichi C, Lee MH, Kenknight BH, Chen LS, Fishbein MC, Karagueuzian HS, Chen PS (2001) Modulation of QT interval by cardiac sympathetic nerve sprouting and the mechanisms of ventricular arrhythmia in a canine model of sudden cardiac death. J Cardiovasc Electrophysiol 12:1068-1073
28. Padmanabhan S, Silvet H, Amin J, Pai RG (2003) Prognostic value of QT interval and QT dispersion in patients with left ventricular systolic dysfunction: Results from a cohort of 2,265 patients with an ejection fraction of B40%. Am Heart J 145:132-138
29. Vrtovec B, Radovancevic R, Thomas CD, Yazdabakhsh AP, Smart FW, Radovancevic B (2006) Prognostic value of the QTc interval after cardiac transplantation. J Heart Lung Transplant 25:29-35